LeonaBio, Inc.

Athira Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases with substantial unmet medical needs, primarily targeting neurological disorders and treatment-resistant oncology. Its lead oncology candidate is lasofoxifene, an orally bioavailable selective estrogen receptor modulator in Phase 3 clinical evaluation for patients with ESR1-mutated metastatic breast cancer. In neurology, the company develops ATH-1105, an orally administered small-molecule positive modulator of the hepatocyte growth factor system being prepared for Phase 2 clinical trials in individuals with amyotrophic lateral sclerosis. The company additionally explores early-stage pipeline assets, such as ATH-1020, to improve neuronal function. Target patient populations consist of individuals living with neurodegenerative conditions and advanced breast cancer.

Athira Pharma conducts global clinical development operations across the United States and Europe, excluding Asia and parts of the Middle East for its in-licensed oncology program. The company is actively pursuing registrational trials enrolling hundreds of study participants. The provided report does not disclose its corporate headquarters location or founding details.

Summary of the business section of LeonaBio's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 19 employees, all of whom were full-time and ten of whom were engaged in research and development activities.”